The potent role of VEGF in angiogenesis is evidenced by the development and clinical use of bevacizumab, an anti-VEGF antibody, for therapy in various types of human cancer including colorectal cancer, lung cancer, renal cancer and ovarian cancer as well as ocular diseases [10,11]. Here, VEGFA is linked to colorectal cancer.